The startup develops medical devices that utilize oral biomarkers for the early diagnosis of pregnancy-related pathologies during the first trimester. By enabling healthcare providers to predict and identify risks, the technology facilitates timely preventive measures and monitoring to improve outcomes for both mothers and infants.
Funding
$700K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for detecting pregnancy-related pathologies like gestational diabetes and pre-eclampsia typically occur in the later stages of pregnancy. This late detection limits the opportunity for early intervention and preventative care, potentially leading to complications for both mother and child. Existing diagnostic methods often lack the sensitivity to identify at-risk pregnancies during the critical first trimester.
Solution
Pregnostica is developing a medical device that enables early detection of pregnancy pathologies during the first trimester through the analysis of oral biomarkers. The technology identifies and quantifies specific molecules in oral fluids, which, combined with clinical data, are processed by a proprietary algorithm to assess the risk of developing conditions like gestational diabetes and pre-eclampsia. This early risk assessment allows healthcare providers to implement timely preventive measures and monitoring strategies, with the goal of reducing complications and improving maternal and infant health outcomes. The diagnostic process involves a simple, non-invasive oral exam performed in approximately 20 seconds.
Target Audience
The primary target audience includes obstetricians, gynecologists, and other healthcare providers involved in prenatal care, as well as health services and hospitals seeking to improve early detection and management of pregnancy-related complications.
Features
- Analysis of oral fluid biomarkers for early detection of pregnancy pathologies
- Proprietary algorithm combining biomarker data with clinical variables for risk assessment
- Non-invasive and rapid oral exam procedure (approximately 20 seconds)
- Early detection of gestational diabetes and pre-eclampsia during the first trimester (11-14 weeks)
- Accuracy rate of over 85% in identifying at-risk pregnancies